CYLD-Mediated Signaling and Diseases

Title:CYLD-Mediated Signaling and Diseases

Volume: 16 Issue: 4

Author(s): Bryan J. Mathis, Yimu Lai, Chen Qu, Joseph S. Janicki and Taixing Cui

Affiliation:

Keywords: Cardiovascular, CYLD, cylindromatosis, deubiquitination, K63, MAPK, NF-kB.

Abstract: The conserved cylindromatosis (CYLD) codes for a deubiquitinating enzyme and is a crucial regulator of diverse cellular processes such as immune responses, inflammation, death, and proliferation. It directly regulates multiple key signaling cascades, such as the Nuclear Factor kappa B [NFkB] and the Mitogen-Activated Protein Kinase (MAPK) pathways, by its catalytic activity on polyubiquitinated key intermediates. Several lines of emerging evidence have linked CYLD to the pathogenesis of various maladies, including cancer, poor infection control, lung fibrosis, neural development, and now cardiovascular dysfunction. While CYLD-mediated signaling is cell type and stimuli specific, the activity of CYLD is tightly controlled by phosphorylation and other regulators such as Snail. This review explores a broad selection of current and past literature regarding CYLD’s expression, function and regulation with emerging reports on its role in cardiovascular disease.

Cite this article as:

Mathis J. Bryan, Lai Yimu, Qu Chen, Janicki S. Joseph and Cui Taixing, CYLD-Mediated Signaling and Diseases, Current Drug Targets 2015; 16 (4) . https://dx.doi.org/10.2174/1389450115666141024152421